Media headlines about Genocea Biosciences (NASDAQ:GNCA) have trended somewhat negative on Tuesday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Genocea Biosciences earned a daily sentiment score of -0.05 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 42.8984454208235 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Several equities research analysts have recently commented on GNCA shares. Piper Jaffray Companies restated an “overweight” rating and set a $5.00 price target on shares of Genocea Biosciences in a research note on Thursday, November 2nd. Zacks Investment Research upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a research note on Monday, October 16th. Stifel Nicolaus cut Genocea Biosciences from a “buy” rating to a “hold” rating and cut their price target for the stock from $15.00 to $2.50 in a research note on Monday, September 25th. Needham & Company LLC cut Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Finally, Cowen restated a “buy” rating and set a $10.00 price target on shares of Genocea Biosciences in a research note on Tuesday, September 26th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $6.25.
Genocea Biosciences (NASDAQ GNCA) traded down $0.05 during trading hours on Tuesday, reaching $1.08. The company’s stock had a trading volume of 543,827 shares, compared to its average volume of 565,889. The stock has a market capitalization of $32.29, a PE ratio of -0.50 and a beta of 1.94. The company has a debt-to-equity ratio of 2.51, a current ratio of 1.55 and a quick ratio of 1.55. Genocea Biosciences has a 1 year low of $1.01 and a 1 year high of $7.29.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.